Novo Nordisk Has Developed a Portfolio of New-Generation Insulins

Novo Nordisk (NVO) has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among GPs (general practitioner) and PCPs (primary care physician). Patients suffering from type 1 diabetes are generally treated by endocrinologists, who focus on factors such as low intra-patient glycemic variability, a flat and stable drug profile, fewer hypoglycemia events, patient convenience, and confidence in the product while prescribing drugs. Because GPs and PCPs don’t focus on glycemic variability and hypoglycemia events, Novo Nordisk’s efforts to raise awareness are expected to drive the adoption of Tresiba in the type 2 diabetes patient population.